Novel perspective on cardiovascular adverse event profiles due to treatment with sodium-glucose transport protein 2 (SGLT2) inhibitors in the Japanese Adverse Drug Event Report (JADER) database

Purpose: Dehydration is an important risk of SGLT2 inhibitors. Although dehydration may lead to thrombosis and embolism, especially cerebral infarction, this concern has not been clinically validated. As a result, cerebral infarction is considered a suspected risk of these inhibitors. To determine whether treatment with SGLT2 inhibitors lead to cardiovascular adverse events, spontaneous adverse event reports were retrieved from a database and assessed using two statistical approaches.